PRIMECAP Odyssey Growth (POGRX)
40.75
-0.02 -0.05%
Aug 10
USD
Key Stats
| Expense Ratio | 0.65% |
| Total Assets Under Management | 9.464B |
| Share Class Assets Under Management | 9.464B |
| Net Asset Value | 40.75 |
| Turnover Ratio | 6.00% |
| 1 Year Fund Level Flows | -4.020B |
Performance & Returns
| Total Return | Cat. Total Return (NAV) | % Rank in Cat. (NAV) | |
|---|---|---|---|
| 1M | 2.67% | 3.73% | 75 |
| 3M | 15.18% | 17.86% | 82 |
| 6M | -1.81% | 9.97% | 95 |
| YTD | -0.46% | 17.13% | 97 |
| 1Y | 12.48% | 27.79% | 93 |
| 3Y | 11.54% | 18.86% | 94 |
| 5Y | 10.93% | 14.16% | 82 |
| 10Y | 13.88% | 15.14% | 71 |
| 15Y | 10.46% | 10.29% | 46 |
| 20Y | -- | 6.42% | -- |
Asset Allocation
| Type | % Net | % Long | % Short |
|---|---|---|---|
| Cash | 1.24% | 1.24% | 0.00% |
| Stock | 98.76% | 98.76% | 0.00% |
| Bond | 0.00% | 0.00% | 0.00% |
| Convertible | 0.00% | 0.00% | 0.00% |
| Preferred | 0.00% | 0.00% | 0.00% |
| Other | 0.00% | 0.00% | 0.00% |
Region Exposure
| Americas | 84.29% |
| North America | 84.29% |
| Latin America | 0.00% |
| Greater Europe | 8.26% |
| United Kingdom | 2.17% |
| Europe Developed | 5.54% |
| Europe Emerging | 0.00% |
| Africa/Middle East | 0.55% |
| Greater Asia | 7.45% |
| Japan | 1.48% |
| Australasia | 0.00% |
| Asia Developed | 1.30% |
| Asia Emerging | 4.67% |
| Market Classification | |
| % Developed Markets | 95.33% |
| % Emerging Markets | 4.67% |
Stock Sector Exposure
| Basic Materials | 0.35% |
| Communication Services | 4.03% |
| Consumer Cyclical | 7.71% |
| Consumer Defensive | 0.14% |
| Energy | 1.71% |
| Financial Services | 7.83% |
| Healthcare | 37.30% |
| Industrials | 11.68% |
| Real Estate | 0.00% |
| Technology | 29.26% |
| Utilities | 0.00% |
Stock Market Capitalization
| Giant | 31.53% |
| Large | 27.29% |
| Medium | 33.87% |
| Small | 7.23% |
| Micro | 0.08% |
Stock Style Exposure
| Large Cap Value | 17.37% |
| Large Cap Blend | 19.91% |
| Large Cap Growth | 21.81% |
| Mid Cap Value | 9.93% |
| Mid Cap Blend | 11.00% |
| Mid Cap Growth | 12.70% |
| Small Cap Value | 0.57% |
| Small Cap Blend | 2.16% |
| Small Cap Growth | 4.55% |
View More Holdings
As of June 30, 2020
Top 10 Holdings
| Symbol | Name | % Weight | Price | % Chg |
|---|---|---|---|---|
| LLY | Eli Lilly and Co | 4.08% | 151.48 | -0.99% |
| SGEN | Seattle Genetics Inc | 3.52% | 153.49 | -2.67% |
| ABMD | Abiomed Inc | 3.27% | 294.87 | -1.72% |
| BMRN | Biomarin Pharmaceutical Inc | 2.67% | 116.84 | -1.19% |
| BIIB | Biogen Inc | 2.57% | 291.00 | -3.08% |
| SPLK | Splunk Inc | 2.56% | 195.64 | -1.14% |
| AMGN | Amgen Inc | 2.54% | 234.83 | -1.40% |
| BABA | Alibaba Group Holding Ltd ADR | 2.47% | 248.75 | +0.25% |
| ETFC | E*TRADE Financial Corp | 2.39% | 53.82 | +2.30% |
| MU | Micron Technology Inc | 2.31% | 47.88 | -2.58% |
Advertisement
Basic Info
| Investment Strategy | |
|---|---|
| The investment seeks to provide long-term capital appreciation. The fund invests primarily in the common stocks of U.S. companies, emphasizing those companies with the potential for above average earnings growth. It may invest in stocks across all market sectors and market capitalizations. Although it has historically invested primarily in large- and mid-capitalization companies, it has also invested a significant portion of its assets in small-capitalization stocks. | |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | POGRX |
| Equity Style | Large Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | US Equity |
| Broad Category | Equity |
| Category Name | Large Growth |
| Prospectus Objective | Growth |
| Fund Owner Firm Name | PRIMECAP Odyssey Funds |
| Benchmark Index | |
| S&P 500 TR USD | 100.0% |
| Reports | |
| One Page Report | Download |
Manager Info
| Name | Tenure |
|---|---|
| Alfred Mordecai | 15.76 yrs |
| James Marchetti | 5.75 yrs |
| Joel Fried | 15.76 yrs |
| M. Ansari | 8.31 yrs |
| Theo Kolokotrones | 15.76 yrs |
Net Fund Flows
| 1M | -389.27M |
| 3M | -1.124B |
| 6M | -2.589B |
| YTD | -2.830B |
| 1Y | -4.020B |
| 3Y | -2.084B |
| 5Y | -982.59M |
| 10Y | 1.670B |
Risk Info
| Beta (5Y) | 1.162 |
| Historical Sharpe Ratio (10Y) | 0.8211 |
| Historical Sortino (All) | 0.6755 |
| Daily Value at Risk (VaR) 1% (All) | 3.65% |
| Monthly Value at Risk (VaR) 1% (All) | 17.41% |
Fundamentals
| Dividend Yield TTM (8-10-20) | 0.50% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Weighted Average PE Ratio | 20.54 |
| Weighted Average Price to Sales Ratio | 1.661 |
| Weighted Average Price to Book Ratio | 3.101 |
| Weighted Median ROE | 15.69% |
| Weighted Median ROA | 4.08% |
| Forecasted Dividend Yield | 1.34% |
| Forecasted PE Ratio | 22.53 |
| Forecasted Price to Sales Ratio | 1.493 |
| Forecasted Price to Book Ratio | 2.750 |
| Number of Holdings | 153 |
Growth Estimates
| Forecasted 5 Yr Earnings Growth | 10.20% |
| Forecasted Book Value Growth | 3.01% |
| Forecasted Cash Flow Growth | 7.05% |
| Forecasted Earnings Growth | 7.60% |
| Forecasted Revenue Growth | 6.78% |
Comparables
Edit| FDSVX | Fidelity® Growth Discovery |
| FNCMX | Fidelity® NASDAQ Composite Index® |
| USNQX | USAA NASDAQ-100 Index |
| FVUSA04AQD | JNL/Mellon Nasdaq® 100 Index A |
| FCNTX | Fidelity® Contrafund® |
Attributes
| Purchase Details | |
|---|---|
| Open to New Investors | Yes |
| Open to Existing Investors | Yes |
| Minimum Initial Investment | 2000.00 USD |
| Minimum Subsequent Investment | 100.00 USD |
| Fees | |
| Actual 12B-1 Fee | -- |
| Actual Management Fee | 0.55% |
| Administration Fee | -- |
| Performance Fee | -- |
| Switching Fee | -- |
| Transaction Fee | -- |
| Maximum Front Load | -- |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | -- |
| Key Dates | |
| Inception Date | 11/1/2004 |
| Termination Date | |
| Last Annual Report Date | 10/31/2019 |
| Last Prospectus Date | 2/28/2020 |
| Attributes | |
| Exchange Traded Share | No |
| Exchange Traded Note | No |
| Enhanced Index Fund | No |
| Fixed Distribution Fund | No |
| High-Net Worth Individual Fund | No |
| Index Fund | No |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |
| General Availability | |
| Available for Insurance Product | No |
| Available for Retirement Plan | No |
| Available for RRSP | No |
Advertisement
